Lisa Walter
Stock Analyst at RBC Capital
(3.09)
# 807
Out of 5,182 analysts
17
Total ratings
53.33%
Success rate
2.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $30 | $14.88 | +101.61% | 4 | Apr 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $32 → $35 | $9.77 | +258.24% | 3 | Mar 19, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $140 → $130 | $87.81 | +48.05% | 2 | Mar 17, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $577.58 | +11.33% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $40.85 | -48.59% | 2 | Feb 25, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $11.25 | +42.22% | 1 | Nov 14, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $14.63 | +166.58% | 2 | Nov 6, 2025 |
Viridian Therapeutics
Apr 7, 2026
Maintains: Outperform
Price Target: $42 → $30
Current: $14.88
Upside: +101.61%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $32 → $35
Current: $9.77
Upside: +258.24%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Outperform
Price Target: $140 → $130
Current: $87.81
Upside: +48.05%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $577.58
Upside: +11.33%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $40.85
Upside: -48.59%
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $11.25
Upside: +42.22%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $14.63
Upside: +166.58%